Close Menu

NEW YORK (GenomeWeb) – Foundation Medicine said today that the US Food and Drug Administration has granted Breakthrough Device designation to a new liquid biopsy assay the firm is developing, an expanded version of its existing FoundationACT assay.

Under the Breakthrough Device program, an expansion of the Expedited Access Pathways program, the FDA works with a test developer to reduce the time and cost from development to approval.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Aug
12
Sponsored by
Truvian

Antibody testing is expected to play an important role in the management of the COVID-19 pandemic. 

Aug
18

As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Oct
09
Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.